c-Myc is a transcription factor that is constitutively and aberrantly expressed in over 70% of human cancers. Its direct inhibition has been shown to trigger rapid tumor regression in mice with only mild and fully reversible side effects, suggesting this to be a viable therapeutic strategy. Here we reassess the challenges of directly targeting c-Myc, evaluate lessons learned from current inhibitors, and explore how future strategies such as miniaturisation of Omomyc and targeting E-box binding could facilitate translation of c-Myc inhibitors into the clinic.
CITATION STYLE
Madden, S. K., de Araujo, A. D., Gerhardt, M., Fairlie, D. P., & Mason, J. M. (2021, December 1). Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc. Molecular Cancer. BioMed Central Ltd. https://doi.org/10.1186/s12943-020-01291-6
Mendeley helps you to discover research relevant for your work.